Lou Yinjun, Ma Yafang, Jin Jie, Zhu Honghu
Department of Hematology, Leukemia Center, The First Affiliated Hospital of Zhejiang University, College of Medicine, Key Laboratory of Hematopoietic Malignancies in Zhejiang Province, Hangzhou, China.
Front Oncol. 2021 Feb 5;10:597601. doi: 10.3389/fonc.2020.597601. eCollection 2020.
Treatment paradigm of acute promyelocytic leukemia (APL) is by no mean the most remarkable story of cancer therapy. Recently, the advent of oral arsenic formulations (oral-arsenic trioxide and Realgar-Indigo Naturalis formula (RIF)) based regimens may provide a therapeutic advance by curing APL with two oral agents. Indeed, the oral RIF plus all-trans-retinoic acid (ATRA) without chemotherapy display highly efficacy in patients with APL. The safety profile of RIF plus ATRA make possible to treat APL patients in a home-based manner during postremission therapy. To our knowledge, RIF was the first commercially available oral arsenic agent approved in China. The RIF plus ATRA regimens are becoming a preferred frontline care for APL in China. In this review, we will discuss the history, current evidences and challengers of RIF-based strategies in APL. More and more APL patients may enjoy a cure with a normal quality-of-life after induction in the near future.
急性早幼粒细胞白血病（APL）的治疗模式绝不是癌症治疗中最引人注目的故事。最近，基于口服砷制剂（口服三氧化二砷和雄黄-靛蓝天然配方（RIF））的治疗方案可能通过使用两种口服药物治愈APL而带来治疗进展。事实上，口服RIF加全反式维甲酸（ATRA）且不进行化疗在APL患者中显示出高度疗效。RIF加ATRA的安全性使得在缓解后治疗期间以居家方式治疗APL患者成为可能。据我们所知，RIF是中国首个获批的商用口服砷剂。RIF加ATRA方案正成为中国APL首选的一线治疗方案。在本综述中，我们将讨论基于RIF的APL治疗策略的历史、当前证据和挑战。在不久的将来，越来越多的APL患者在诱导治疗后可能会以正常的生活质量获得治愈。
